Geneviève Pilon

Dr. Geneviève Pilon

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
MMMeriem Messaoudene
Meriem Messaoudene
RPReilly Pidgeon
Reilly Pidgeon
CRCorentin Richard
Corentin Richard
MPMayra Ponce
Mayra Ponce
KDKhoudia Diop
Khoudia Diop
BRBertrand Routy
Bertrand Routy
Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance. Significance: The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial. This article is highlighted in the In This Issue feature, p. 873

1 December 2017 in Molecular Metabolism
Verified
Journal Article
Open access
FAFernando F. Anhê
Fernando F. Anhê
RNRenato Nachbar
Renato Nachbar
TVThibault V. Varin
Thibault V. Varin
VVVanessa Rodrigues Vilela
Vanessa Rodrigues Vilela
SDStéphanie Dudonné
Stéphanie Dudonné
AMAndré Marette
André Marette
Previous studies have reported that polyphenol-rich extracts from various sources can prevent obesity and associated gastro-hepatic and metabolic disorders in diet-induced obese (DIO) mice. However, whether such extracts can reverse obesity-linked metabolic alterations remains unknown. In the present study, we aimed to investigate the potential of a polyphenol-rich extract from cranberry (CE) to reverse obesity and associated metabolic disorders in DIO-mice. Mice were pre-fed either a Chow or a High Fat-High Sucrose (HFHS) diet for 13 weeks to induce obesity and then treated either with CE (200 mg/kg, Chow + CE, HFHS + CE) or vehicle (Chow, HFHS) for 8 additional weeks. CE did not reverse weight gain or fat mass accretion in Chow- or HFHS-fed mice. However, HFHS + CE fully reversed hepatic steatosis and this was linked to upregulation of genes involved in lipid catabolism (e.g., PPARα) and downregulation of several pro-inflammatory genes (eg, COX2, TNFα) in the liver. These findings were associated with improved glucose tolerance and normalization of insulin sensitivity in HFHS + CE mice. The gut microbiota of HFHS + CE mice was characterized by lower Firmicutes to Bacteroidetes ratio and a drastic expansion of Akkermansia muciniphila and, to a lesser extent, of Barnesiella spp, as compared to HFHS controls. Taken together, our findings demonstrate that CE, without impacting body weight or adiposity, can fully reverse HFHS diet-induced insulin resistance and hepatic steatosis while triggering A. muciniphila blooming in the gut microbiota, thus underscoring the gut-liver axis as a primary target of cranberry polyphenols.

24 September 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
Marion REGNIERMarion REGNIER
Marion REGNIER
MRMarialetizia RASTELLI
Marialetizia RASTELLI
AMArianne Morissette
Arianne Morissette
FSFrancesco Suriano
Francesco Suriano
TRTiphaine Le Roy
Tiphaine Le Roy
Patrice CaniPatrice Cani
Patrice Cani
Obesity and obesity-related disorders, such as type 2 diabetes have been progressively increasing worldwide and treatments have failed to counteract their progression. Growing evidence have demonstrated that gut microbiota is associated with the incidence of these pathologies. Hence, the identification of new nutritional compounds, able to improve health through a modulation of gut microbiota, is gaining interest. In this context, the aim of this study was to investigate the gut-driving effects of rhubarb extract in a context of diet-induced obesity and diabetes. Eight weeks old C57BL6/J male mice were fed a control diet (CTRL), a high fat and high sucrose diet (HFHS) or a HFHS diet supplemented with 0.3% (g/g) of rhubarb extract for eight weeks. Rhubarb supplementation fully prevented HFHS-induced obesity, diabetes, visceral adiposity, adipose tissue inflammation and liver triglyceride accumulation, without any modification in food intake. By combining sequencing and qPCR methods, we found that all these effects were associated with a blooming of Akkermansia muciniphila, which is strongly correlated with increased expression of Reg3γ in the colon. Our data showed that rhubarb supplementation is sufficient to protect against metabolic disorders induced by a diet rich in lipid and carbohydrates in association with a reciprocal interaction between Akkermansia muciniphila and Reg3γ.

1 July 2015 in PharmaNutrition
Verified
Journal Article
Closed access
SDStéphanie Dudonné
Stéphanie Dudonné
TVThibault V. Varin
Thibault V. Varin
FAFernando Forato Anhê
Fernando Forato Anhê
PDPascal Dubé
Pascal Dubé
Denis RoyDenis Roy
Denis Roy
YDYves Desjardins
Yves Desjardins

17 December 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
MFMaximilien Franck
Maximilien Franck
JMJuan De Toro Martín
Juan De Toro Martín
VGVéronique Garneau
Véronique Garneau
VGValerie Guay
Valerie Guay
MKMichèle Kearney
Michèle Kearney
Marie-Claude VohlMarie-Claude Vohl
Marie-Claude Vohl
Consumption of red raspberries has been reported to exert acute beneficial effects on postprandial glycemia, insulinemia, triglyceridemia, and cytokine levels in metabolically disturbed subjects. In a two-arm parallel-group, randomized, controlled trial, 59 subjects with overweight or abdominal obesity and with slight hyperinsulinemia or hypertriglyceridemia were randomized to consume 280 g/day of frozen raspberries or to maintain their usual diet for 8 weeks. Primary analyses measured metabolic differences between the groups. Secondary analyses performed with omics tools in the intervention group assessed blood gene expression and plasma metabolomic changes following the raspberry supplementation. The intervention did not significantly affect plasma insulin, glucose, inflammatory marker concentrations, nor blood pressure. Following the supplementation, 43 genes were differentially expressed, and several functional pathways were enriched, a major portion of which were involved in the regulation of cytotoxicity, immune cell trafficking, protein signal transduction, and interleukin production. In addition, 10 serum metabolites were found significantly altered, among which β-alanine, trimethylamine N-oxide, and bioactive lipids. Although the supplementation had no meaningful metabolic effects, these results highlight the impact of a diet rich in raspberry on the immune function and phospholipid metabolism, thus providing novel insights into potential immune-metabolic pathways influenced by regular raspberry consumption.

26 March 2014 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
SDStéphanie Dudonné
Stéphanie Dudonné
PDPascal Dubé
Pascal Dubé
GPGeneviève Pilon
Geneviève Pilon
AMAndré Marette
André Marette
HJHélène Jacques
Hélène Jacques
YDYves Desjardins
Yves Desjardins